Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: BHC stock price vs FTI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at FTI's multiple
Needs FTI P/E.
Implied fair value · at BHC's multiple
Needs BHC P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: BHC FY 2025 (ended Dec 31, 2025) · FTI FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 10% equity / 90% debt · EV / Revenue 2.16x · EV / EBITDA 9.16x
Capital structure 99% equity / 1% debt · EV / Revenue 3.10x · EV / EBITDA 18.66x
FTI carries the larger enterprise value at $30.74B against $22.19B; BHC trades on the lower EV / Revenue multiple (2.16x vs 3.10x); BHC on the lower EV / EBITDA (9.16x vs 18.66x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Bausch Health Companies Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
TechnipFMC plc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-37.98x
0.14x
Net debt / EBITDA
Leverage against operating earnings
8.15x
-0.34x
Cash and equivalents
Liquid reserves on the balance sheet
$1.31B
$1.03B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AbbVie Inc.
BHC vs ABBV
Organon & Co.
BHC vs OGN
TEVA PHARMACEUTICAL INDUSTRIES LTD
BHC vs TEVA
SUPERNUS PHARMACEUTICALS, INC.
BHC vs SUPN
ANI PHARMACEUTICALS INC
BHC vs ANIP
SCHLUMBERGER LIMITED/NV
BHC vs SLB
Baker Hughes Co
BHC vs BKR
HALLIBURTON CO
BHC vs HAL
NOV Inc.
BHC vs NOV
Weatherford International plc
BHC vs WFRD
$21.04B
$464.30M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
